Global Hematopoietic Stem Cells Transplantation Market Highlights over 2022 – 2031
The global hematopoietic stem cells transplantation market is estimated to grow at a CAGR of ~8% over the forecast period, i.e., 2022 – 2031. Hematopoietic stem cells have the potency to produce more blood cells, i.e., red blood cells, white blood cells, and platelets. These stem cells are need to treat diseases related to blood, such as, blood cancer (leukemia, and lymphoma), auto-immune diseases, immunodeficiency, and genetic disorders. The growth of the market can be attributed to the increasing prevalence of blood cancer worldwide. According to a report by the International Agency of Research on Cancer (IARC), globally out of every 100,000 individuals, 336,669 individuals were suffering from leukemia, 64,067 with Hodgkin lymphoma, and 399,610 with non-Hodgkin lymphoma, in 202o. Moreover, growing adoption of stem cell transplants across the medical industry is estimated to further drive the market growth. Along with this, the growing awareness amongst people regarding early diagnosis of rare diseases, combined with the adoption of advanced treatment methods, and growing healthcare expenditure are foreseen to promote the market growth. As per the statistics by the World Bank, 9.856% of the global GDP was spent for healthcare in 2018.
The market is segmented by disease type, into acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, and others. Out of these, the multiple myeloma segment is anticipated to hold a substantial size in the global hematopoietic stem cells transplantation market over the forecast period on account of high prevalence of multiple myeloma amongst adults globally. For instance, according to IARC database, multiple myeloma was prevalent in 131,518 out of every 100,000 individuals, in 2020. This high rate of incidences is anticipated to boost the segment growth over the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Hematopoietic Stem Cells Transplantation Market Regional Synopsis
On the basis of geographical analysis, the global hematopoietic stem cells transplantation market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in the North America region is anticipated to gain the largest market share throughout the forecast period on the account of the high prevalence of leukemia and lymphoma in the region. According to the data by the American Cancer Society, in the United States, about 60,650 new cases of leukemia were reported in 2021, out of which, 20,050 cases of acute myeloid leukemia (AML) were reported.
The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of growing incidences of blood cancer, along with rising health awareness amongst the people. Moreover, the gradually yet constantly increasing disposable income of the people, is estimated to propel the market growth, as more patients will be able to afford the costly stem cell transplants. On the other hand, the market in Europe region is also anticipated to grab a considerable share in the market during the forecast period, owing to the overall increase in the success rate of transplants, a technologically advanced healthcare system, and a high-income population.
The global hematopoietic stem cells transplantation market is further classified on the basis of region as follows:
North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
Our in-depth analysis of the global hematopoietic stem cells transplantation market includes the following segments:
By Transplant Type
By Disease Type
Top Featured Companies Dominating the Market
FREQUENTLY ASKED QUESTIONS
Increasing prevalence of blood cancer, and other hematopoietic disorders is estimated to boost the market growth.
The market is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2022 – 2031.
The major players in the market are Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., ViaCord, LLC, and Cynata Therapeutics Limited.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by transplant type, disease type, application, and by region.
The bone marrow transplant (BMT) segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities.
Very high cost of stem cell transplant is estimated to hamper the market growth.
The North America region is anticipated to provide more business opportunities over the forecast period on the back of growing incidences of blood cancer in the region.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization